Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1993 1
1994 2
2000 1
2001 2
2002 1
2003 1
2005 4
2006 5
2007 7
2008 1
2009 3
2010 1
2011 3
2012 6
2013 5
2014 4
2015 3
2016 2
2017 2
2018 2
2019 2
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Bisphosphonate - Induced Nephropathy"
Page 1
Drug-induced glomerular disease: direct cellular injury.
Markowitz GS, Bomback AS, Perazella MA. Markowitz GS, et al. Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1291-9. doi: 10.2215/CJN.00860115. Epub 2015 Apr 10. Clin J Am Soc Nephrol. 2015. PMID: 25862776 Free PMC article. Review.
The potential of medications to cause kidney injury is well known. Although nephrotoxicity is most commonly associated with injury in the tubulointerstitial compartment as either acute tubular necrosis or acute interstitial nephritis, a growing body of literature has also …
The potential of medications to cause kidney injury is well known. Although nephrotoxicity is most commonly associated with injury in …
Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.
Cowan A, Jeyakumar N, McArthur E, Fleet JL, Kanagalingam T, Karp I, Khan T, Muanda FT, Nash DM, Silver SA, Thain J, Weir MA, Garg AX, Clemens KK. Cowan A, et al. J Bone Miner Res. 2023 May;38(5):650-658. doi: 10.1002/jbmr.4804. Epub 2023 Apr 9. J Bone Miner Res. 2023. PMID: 36970786 Free article.
Denosumab can be used in patients with chronic kidney disease (CKD) but has been linked with cases of severe hypocalcemia. ...In those with an eGFR <15 or receiving maintenance dialysis, the incidence of mild and severe hypocalcemia was 24.1% (95% CI 18.1, 30.7) and 14. …
Denosumab can be used in patients with chronic kidney disease (CKD) but has been linked with cases of severe hypocalcemia. ...In thos …
Bone Metastasis from Renal Cell Carcinoma.
Chen SC, Kuo PL. Chen SC, et al. Int J Mol Sci. 2016 Jun 22;17(6):987. doi: 10.3390/ijms17060987. Int J Mol Sci. 2016. PMID: 27338367 Free PMC article. Review.
The presence of bone metastasis in RCC is also associated with poor prognosis. Bone-targeted treatment using bisphosphonate and denosumab can reduce skeletal complications in RCC, but does not cure the disease or improve survival. Elucidating the molecular mechanism …
The presence of bone metastasis in RCC is also associated with poor prognosis. Bone-targeted treatment using bisphosphonate an …
Low Bone Density and Bisphosphonate Use and the Risk of Kidney Stones.
Prochaska M, Taylor E, Vaidya A, Curhan G. Prochaska M, et al. Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1284-1290. doi: 10.2215/CJN.01420217. Epub 2017 Jun 2. Clin J Am Soc Nephrol. 2017. PMID: 28576907 Free PMC article.
Small studies with short follow-up reported reduced 24-hour urine calcium excretion with bisphosphonate use. We examined history of low bone density and bisphosphonate use and the risk of incident kidney stone as well as the association with 24-hour calcium e …
Small studies with short follow-up reported reduced 24-hour urine calcium excretion with bisphosphonate use. We examined history of l …
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Strampel W, Emkey R, Civitelli R. Strampel W, et al. Drug Saf. 2007;30(9):755-63. doi: 10.2165/00002018-200730090-00003. Drug Saf. 2007. PMID: 17722968 Review.
Bisphosphonates are the most commonly prescribed medications for the treatment of osteoporosis. ...Symptoms of influenza-like illness have been associated with both IV and oral bisphosphonates. Osteonecrosis of the jaw has also been associated with IV bisphosphon …
Bisphosphonates are the most commonly prescribed medications for the treatment of osteoporosis. ...Symptoms of influenza-like illness …
The safety of zoledronic acid.
Lipton A. Lipton A. Expert Opin Drug Saf. 2007 May;6(3):305-13. doi: 10.1517/14740338.6.3.305. Expert Opin Drug Saf. 2007. PMID: 17480179 Review.
The safety profile of zoledronic acid in this patient population is well established from the databases of several large, randomized, Phase III trials and postmarketing clinical experience. Zoledronic acid is well tolerated, with predictable side effects, primarily transie …
The safety profile of zoledronic acid in this patient population is well established from the databases of several large, randomized, Phase …
Vascular calcification and arterial stiffness in chronic kidney disease: implications and management.
Toussaint ND, Kerr PG. Toussaint ND, et al. Nephrology (Carlton). 2007 Oct;12(5):500-9. doi: 10.1111/j.1440-1797.2007.00823.x. Nephrology (Carlton). 2007. PMID: 17803475 Review.
Cardiovascular (CV) disease is the commonest cause of mortality in patients with chronic kidney disease (CKD). Vascular calcification (VC), induced by calcium and phosphate excess and uraemia, is a major risk factor and is independently associated with CV events and …
Cardiovascular (CV) disease is the commonest cause of mortality in patients with chronic kidney disease (CKD). Vascular calcification …
Glomerular diseases seen with cancer and chemotherapy: a narrative review.
Jhaveri KD, Shah HH, Calderon K, Campenot ES, Radhakrishnan J. Jhaveri KD, et al. Kidney Int. 2013 Jul;84(1):34-44. doi: 10.1038/ki.2012.484. Epub 2013 Jan 30. Kidney Int. 2013. PMID: 23364518 Free article. Review.
Chemotherapy agents such as interferon, anti-vascular endothelial growth factor agents, tyrosine kinase inhibitors, and bisphosphonates have also been associated with various glomerular diseases and thrombotic microangiopathy. Failure to recognize certain paraneopla …
Chemotherapy agents such as interferon, anti-vascular endothelial growth factor agents, tyrosine kinase inhibitors, and bisphosphonates …
Bisphosphonate treatment of tumor-induced hypercalcemia in a toddler: case report and review of related literature.
Mastrandrea LD, Albini CH. Mastrandrea LD, et al. Endocr Pract. 2006 Nov-Dec;12(6):670-5. doi: 10.4158/EP.12.6.670. Endocr Pract. 2006. PMID: 17229665 Review.
Because of refractory hypercalcemia, intravenously administered bisphosphonate was used. Within 12 hours after bisphosphonate infusion, the serum calcium level declined from 14.9 mg/dL to 10.9 mg/dL. ...Hypercalcemia in the pediatric population can be treated effect …
Because of refractory hypercalcemia, intravenously administered bisphosphonate was used. Within 12 hours after bisphosphonate …
Zoledronic acid and ibandronate-induced nephrotoxicity in 2D and 3D proximal tubule cells derived from human and rat.
Valencia LJ, Tseng M, Chu ML, Yu L, Adedeji AO, Kiyota T. Valencia LJ, et al. Toxicol Sci. 2024 Feb 28;198(1):86-100. doi: 10.1093/toxsci/kfad123. Toxicol Sci. 2024. PMID: 38059598
Drug-induced proximal tubule (PT) injury remains a serious safety concern throughout drug development. ...Furthermore, ibandronate-exposed hRPTEC/TERT1s and rPPTECs produced higher levels of inflammatory and kidney injury biomarkers compared to zoledronic acid, indi …
Drug-induced proximal tubule (PT) injury remains a serious safety concern throughout drug development. ...Furthermore, ibandronate-ex …
54 results